FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Vivien Mautner

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Genes & Molecular Sequences

Anatomy

Physiology

Devices

Gene Transfer Techniques

Disorders

Neoplasms

Co-author Network

Publications

TOP 3
Geothy Chakupurakal; David Onion; Mark Cobbold; Vivien Mautner; Paul A H Moss
Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7.
David Onion; Prashant Patel; Robert G Pineda; Nicholas James; Vivien Mautner
Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer.
Prashant Patel; J Graham Young; Vivien Mautner; Daniel Ashdown; Sarah Bonney; Robert G Pineda; Stuart I Collins; Peter F Searle; Diana Hull; Elizabeth Peers; John Chester; D Michael Wallace; Alan Doherty; Hing Leung; Lawrence S Young; Nicholas James
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Vivien Mautner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Geothy Chakupurakal; David Onion; Mark Cobbold; Vivien Mautner; Paul A H Moss
Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7.
AIDS (London, England) 2010;24(2):205-10.
2009: David Onion; Prashant Patel; Robert G Pineda; Nicholas James; Vivien Mautner
Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer.
Human gene therapy 2009;20(11):1249-58.
2009: Prashant Patel; J Graham Young; Vivien Mautner; Daniel Ashdown; Sarah Bonney; Robert G Pineda; Stuart I Collins; Peter F Searle; Diana Hull; Elizabeth Peers; John Chester; D Michael Wallace; Alan Doherty; Hing Leung; Lawrence S Young; Nicholas James
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984].
Molecular therapy : the journal of the American Society of Gene Therapy 2009;17(7):1292-9.
2008: M Bazan-Peregrino; R C Carlisle; R Hernandez-Alcoceba; R Iggo; Krisztian Homicsko; Kerry D Fisher; G Halldén; Vivien Mautner; Y Shen; Leonard W Seymour
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Human gene therapy 2008;19(9):873-86.
2008: Nicola K Green; Joanne Morrison; Sarah Hale; Simon S Briggs; Mark Stevenson; Vladimir Subr; Karel Ulbrich; Lois Chandler; Vivien Mautner; Leonard W Seymour; Kerry D Fisher
Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
The journal of gene medicine 2008;10(3):280-9.
2008: J G Young; Nicola K Green; Vivien Mautner; Peter F Searle; Lawrence S Young; Nicholas James
Combining gene and immunotherapy for prostate cancer.
Prostate cancer and prostatic diseases 2008;11(2):187-93.
2007: David Onion; Laura J Crompton; Donald W Milligan; Paul A H Moss; Steven P Lee; Vivien Mautner
The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein.
The Journal of general virology 2007;88(Pt 9):2417-25.
2007: Vivien Mautner
Growth and purification of enteric adenovirus type 40.
Methods in molecular medicine 2007;130():145-56.
2006: Robert C Carlisle; Simon S Briggs; Ashley Hale; Nicola K Green; Kerry D Fisher; Tomás Etrych; Karel Ulbrich; Vivien Mautner; Leonard W Seymour
Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.
Gene therapy 2006;13(22):1579-86.
2006: Mark Lyons; David Onion; Nicola K Green; Kriss Aslan; Ratna Rajaratnam; Miriam Bazan-Peregrino; Sue Phipps; Sarah Hale; Vivien Mautner; Leonard W Seymour; Kerry D Fisher
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(1):118-28.
2006: Daniel H Palmer; Lawrence S Young; Vivien Mautner
Cancer gene-therapy: clinical trials.
Trends in biotechnology 2006;24(2):76-82.
2006: Mark Stevenson; E Boos; C Herbert; Ashley Hale; N Green; M Lyons; L Chandler; Karel Ulbrich; N van Rooijen; Vivien Mautner; K Fisher; L Seymour
Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells.
Gene therapy 2006;13(4):356-68.
2006: Lawrence S Young; Peter F Searle; David Onion; Vivien Mautner
Viral gene therapy strategies: from basic science to clinical application.
The Journal of pathology 2006;208(2):299-318.
2005: James D Ramsden; Malcolm A Buchanan; Stuart Egginton; John C Watkinson; Vivien Mautner; Sundaram Ramasamy
Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin, vascular endothelial growth factor, and fibroblast growth factor signaling.
Endocrinology 2005;146(7):2895-902.
2004: Peter F Searle; Ming-Jen Chen; Longqin Hu; Paul R Race; Andrew L Lovering; Jane I Grove; Christopher Guise; Mansooreh Jaberipour; Nicholas James; Vivien Mautner; Lawrence S Young; David J Kerr; Andrew Mountain; Scott A White; Eva I Hyde
Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Clinical and experimental pharmacology & physiology 2004;31(11):811-6.
2004: Nicola K Green; C W Herbert; Sarah J M Hale; Ashley Hale; Vivien Mautner; R Harkins; Terry W Hermiston; Karel Ulbrich; Kerry D Fisher; Leonard W Seymour
Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus.
Gene therapy 2004;11(16):1256-63.
2004: Ming-Jen Chen; Nicola K Green; Gary M Reynolds; Joanne R Flavell; Vivien Mautner; David J Kerr; Lawrence S Young; Peter F Searle
Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Gene therapy 2004;11(14):1126-36.
2004: Chakrabarti Suparno; Donald W Milligan; Paul A H Moss; Vivien Mautner
Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management.
Leukemia & lymphoma 2004;45(5):873-85.
2004: Daniel H Palmer; Vivien Mautner; Darius F Mirza; Simon Oliff; Winald Gerritsen; J R M van der Sijp; Stefan G Hubscher; Gary Reynolds; Sarah Bonney; Ratna Rajaratnam; Diana Hull; Mark Horne; John Ellis; Andrew Mountain; Simon Hill; Peter A Harris; Peter F Searle; Lawrence S Young; Nicholas James; David J Kerr
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1546-52.
2004: Nicola K Green; David J Kerr; Vivien Mautner; Peter A Harris; Peter F Searle
The nitroreductase/CB1954 enzyme-prodrug system.
Methods in molecular medicine 2004;90():459-77.
2003: Emma L Davies; James D Ramsden; Helen C Cocks; Peter F Searle; John C Watkinson; Hikaru Ueno; Ann Logan; Jayne A Franklyn; Vivien Mautner; Sundaram Ramasamy
Adenovirus-mediated expression of dominant negative fibroblast growth factor (FGF) receptor 1 in thyroid cells blocks FGF effects and reduces goitrogenesis in mice.
The Journal of clinical endocrinology and metabolism 2003;88(9):4472-80.
2003: Leonard W Seymour; Kerry D Fisher; Nicola K Green; Sarah J M Hale; M Lyons; Vivien Mautner; Shibani Nicum; David Onion; David Oupický; Mark Stevenson; Karel Ulbrich
Adenovirus retargeting and systemic delivery.
Ernst Schering Research Foundation workshop 2003;(43):107-14.
2002: Daniel H Palmer; Vivien Mautner; David J Kerr
Clinical experience with adenovirus in cancer therapy.
Current opinion in molecular therapeutics 2002;4(5):423-34.
2002: Suparno Chakrabarti; Vivien Mautner; Husam Osman; Kathryn E Collingham; Christopher Fegan; Paul E Klapper; Paul A H Moss; Donald W Milligan
Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.
Blood 2002;100(5):1619-27.
2001: Robert C Carlisle; Thierry Bettinger; Manfred Ogris; S Hale; Vivien Mautner; Leonard W Seymour
Adenovirus hexon protein enhances nuclear delivery and increases transgene expression of polyethylenimine/plasmid DNA vectors.
Molecular therapy : the journal of the American Society of Gene Therapy 2001;4(5):473-83.
2001: GA Chung-Faye; Ming-Jen Chen; Nicola K Green; A Burton; D Anderson; Vivien Mautner; Peter F Searle; David J Kerr
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
Gene therapy 2001;8(20):1547-54.
2001: Lawrence S Young; Vivien Mautner
The promise and potential hazards of adenovirus gene therapy.
Gut 2001;48(5):733-6.
2001: Kerry D Fisher; Y Stallwood; Nicola K Green; Karel Ulbrich; Vivien Mautner; Leonard W Seymour
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.
Gene therapy 2001;8(5):341-8.
2000: Kerry D Fisher; Karel Ulbrich; Vladimir Subr; C M Ward; Vivien Mautner; D Blakey; Leonard W Seymour
A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression.
Gene therapy 2000;7(15):1337-43.
2000: SJ Weedon; Nicola K Green; Iain A McNeish; MG Gilligan; Vivien Mautner; Christopher J Wrighton; Andrew Mountain; Lawrence S Young; David J Kerr; Peter F Searle
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
International journal of cancer. Journal international du cancer 2000;86(6):848-54.
2000: Y Stallwood; Kerry D Fisher; Phillip H Gallimore; Vivien Mautner
Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients.
Gene therapy 2000;7(8):637-43.
2000: J P Latham; Peter F Searle; Vivien Mautner; Nicholas James
Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Cancer research 2000;60(2):334-41.
1999: Vivien Mautner; A Bailey; V Steinthorsdottir; R Ullah; A Rinaldi
Properties of the adenovirus type 40 E1B promoter that contribute to its low transcriptional activity.
Virology 1999;265(1):10-9.
1998: Iain A McNeish; Nicola K Green; MG Gilligan; MJ Ford; Vivien Mautner; Lawrence S Young; David J Kerr; Peter F Searle
Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
Gene therapy 1998;5(8):1061-9.
1998: Peter F Searle; Vivien Mautner
Adenoviral vectors: not to be sneezed at.
Gene therapy 1998;5(6):725-7.